Faron Pharmaceuticals Unveils Groundbreaking Study on Clever-1 Receptor and Immunotherapy Resistance

Strategic Insights -

A peer-reviewed study published in the journal Theranostics reveals that a secreted, truncated form of the Clever-1 receptor (sClever-1) acts as an immunosuppressive mediator in cancer, impairing T-cell responses and contributing to resistance to anti-programmed cell death protein-1 (PD-1) immunotherapies. Researchers found that high levels of sClever-1 were associated with resistance to anti-PD-1 therapy, and the study demonstrated that Faron's bexmarilimab treatment significantly reduced the release of sClever-1 in cancer patients. These findings provide significant new insights into the biology of Clever-1, the target of Faron's immunotherapy asset, bexmarilimab.

Key Takeaways:

  • A secreted, truncated form of the Clever-1 receptor (sClever-1) is identified as a key immunosuppressive mediator in cancer, impairing T-cell responses.
  • sClever-1 operates independently of the cellular receptor and contributes to an immunosuppressive environment.
  • The study demonstrates that bexmarilimab treatment significantly reduces the release of sClever-1 in cancer patients, correlating with decreased engagement on T cells.
  • High levels of sClever-1 are associated with resistance to anti-PD-1 checkpoint inhibitors.
  • sClever-1 is identified as a potential biomarker to guide immunotherapy strategies.
  • The study suggests that high levels of sClever-1 are associated with resistance to anti-PD-1 therapy in cancer patients.
  • The addition of a recombinant sClever-1 protein led to a significant increase in the secretion of TGF-β, a key immunosuppressive cytokine, in patient-derived tumor explants.
  • Bexmarilimab's ability to reduce systemic levels of the immunosuppressive sClever-1 provides a clear rationale for its potential to overcome immunotherapy resistance.

Statistics:

  • The study analyzed plasma samples from breast cancer patients (n=139) and bexmarilimab-treated clinical trial participants (n=193) as well as healthy donors.
  • High levels of sClever-1 were significantly enriched in the plasma of cancer patients compared to healthy individuals.
  • The reduction in circulating sClever-1 after bexmarilimab treatment correlated with decreased engagement on T cells.

Sources:

  • Faron Pharmaceuticals Ltd. Press Release
  • Theranostics, Volume Number and Date, "Secreted form of Clever-1 receptor contributes to cancer immunosuppression and resistance to PD-1 inhibitors"
  • Cancer Research UK (CRUK)
  • NIHR Birmingham Biomedical Research Centre
  • Research Council of Finland
  • Sigrid Juselius Foundation